L-654,284 a new potent and selective α2-adrenoceptor antagonist

Summary L-654,284 ((2R, 12bS)-N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]-furo[2,3-a] quinolizine-2-yl)-N-methyl-2-hydroxyethanesulfonamide) was tested in several in vitro and in vivo models for ₂-adrenoceptor antagonist activity and compared to several reference agents. In vitro L-654,284 competed for the binding of ³H-clonidine or ³H-rauwolscine (K _i's 0.8 nM, 1.1 nM) and blocked the presynaptic effects of clonidine in the rat isolated vas deferens (pA₂, 9.1). L-654,284 exhibited marked ₂- vs. ₁-adrenoceptor selectivity in vitro, inhibiting ³H-prazosin binding with a K _i of 110 nM and blocking the effects of methoxamine on the vas deferens with a pA₂ of 7.5. In vivo L-654,284 at 22 nmoles/kg i.v. doubled the ED₅₀ of clonidine to produce mydriasis in rats. Given orally, the potency of L-654,284 in this test was reduced by a factor of 5.5. L-654,284 also potently increased cerebrocortical NE turnover in the rat, another in vivo index of ₂-adrenoceptor blockade in the central nervous system. In the periphery, L-654,284 demonstrated ₂-adrenoceptor selectivity by preferentially blocking the pressor effects of UK 14304 versus those of methoxamine in the pithed rat. Overall, L-654,284 was generally a more potent ₂-adrenoceptor antagonist than RX 781094 with comparable ₂/₁ selectivity and was several times more potent and ₂-selective than WY 26703 or yohimbine. In addition, L-654,284 had better (5–6 times) oral bioavailability than RX 781094 or WY 26703.     

The effects of the 2-amino-tetrahydronaphthalene derivative M7, a selective α2-adrenoceptor agonist in vitro

Summary M7 was originally reported to be a selective presynaptic ₂-adrenoceptor agonist in the pithed rat preparation. Subsequent work showed that M7 also stimulated postsynaptic ₂-adrenoceptors in this preparation, producing a pressor response. We have now investigated the selectivity of M7 for ₂- and ₁-adrenoceptors in vitro. Our results demonstrate that M7 is very potent in stimulating presynaptic ₂-adrenoceptors in the rat vas deferens and postsynaptic ₂-adrenoceptors in the dog saphenous vein. However, at higher doses M7 is also an ₁-adrenoceptor agonist, its ED₅₀ at ₁-adrenoceptors being approximately 60 fold greater than that at postsynaptic ₂-adrenoceptors. It is clear that the postsynaptic effects of M7 will depend upon the relative proportions of ₁- and ₂-adrenoceptors contained in the tissue under study.     

The pharmacology of RS-15385-197, a potent and selective α2-adrenoceptor antagonist

1 RS-15385-197 ((8aR, 12aS, 13aS)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-3-methoxy-12-(methylsul- phonyl)-6H-isoquino [2,1-g][1,6]-naphthyridine) was evaluated in a series of in vitro and in vivo tests as an antagonist at α₂-adrenoceptors.2 RS-15385-197 had a pK_i of 9.45 for α₂-adrenoceptors in the rat cortex (pA₂ in the guinea-pig ileum of 9.72), whereas the 8aS, 12aR, 13aR enantiomer, RS-15385-198, had a pK_i of only 6.32 (pA₂ 6.47) indicating a high degree of stereoselectivity. The racemate RS-15385-196 had a pK_i of 9.18.3 RS-15385-197 showed unprecedented α₂ vs. α₁ adrenoceptor selectivity in vitro. In the rat cortex, RS-15385-197 had a pK_i of 9.45 in displacing [³H]-yohimbine and 5.29 in displacing [³H]-prazosin (α₂/α₁ selectivity ratio in binding experiments > 14000). The compound had a pA₂ of 9.72 as a competitive antagonist of the inhibitory effects of UK-14,304 in transmurally-stimulated guinea-pig ileum and 10.0 against BHT-920-induced contractions in dog saphenous vein (DSV); this latter value was unaltered by phenoxybenzamine. An apparent pK_B of 5.9 was obtained against cirazoline-induced contractions in DSV, whilst a pA₂ of 6.05 was obtained against phenylephrine-induced contractions in the rabbit aorta (α₂/α₁ selectivity ratio in functional experiments > 4000).4 RS-15385-197 was highly selective for α₂-adrenoceptors over other receptors: the compound showed low affinity for 5-HT_1A (pK_i 6.50) and 5-HT_1D (pK_i 7.00) receptor subtypes, and even lower affinity (pK_i≤5) for other 5-HT receptor subtypes, dopamine receptors, muscarinic cholinoceptors, β-adrenoceptors and dihydropyridine binding sites. RS-15385-197 was devoid of affinity for the non-adrenoceptor imidazoline binding site, labelled by [³H]-idazoxan, which provides further evidence that these sites are not related to α₂-adrenoceptors. In the DSV, contractile responses to 5-hydroxytryptamine (5-HT) were unaffected by a concentration of 1 μM RS-15385-197.5 RS-15385-197 was non-selective for the α_2A- and α_2B-adrenoceptor subtypes in that the pK_i for the α_2A-adrenoceptor in human platelets was 9.90 and the pK_i for the α_2B-adrenoceptor in rat neonate lung was 9.70. However, RS-15385-197 showed lower affinity for the α₂-adrenoceptor subtype in hamster adipocytes (pK_i 8.38).6 In anaesthetized rats, RS-15385-197 was a potent antagonist of the mydriasis response induced by UK-14,304 or clonidine (AD₅₀ 5 and 7 μg kg^-1, i.v., respectively; 96 μg kg^-1, p.o.) and of UK-14,304-induced pressor responses in pithed rats (AD₅₀ 7 μg kg^-1, i.v.); the compound therefore is both centrally and orally active. Even at a high dose (10 mg kg^-1, i.v.), RS-15385-197 did not antagonize pressor responses to cirazoline in pithed rats, indicating that the selectivity for α₂ vs. α₁-adrenoceptors was maintained in vivo.8 RS-15385-197 is therefore a very potent, selective, competitive α₂-adrenoceptor antagonist, both in vitro and in vivo, is orally active and readily penetrates the brain. It will thus be a powerful pharmacological tool for exploring the various physiological roles of α₂-adrenoceptors.     

Noradrenaline-induced contraction of human saphenous vein and human internal mammary artery: involvement of different α-adrenoceptor subtypes

Although saphenous veins and internal mammary arteries are commonly used for coronary artery bypass grafting, only a very few comparative studies are available on alpha-adrenoceptor-mediated vasoconstriction in these vessels. Thus, we determined, in isolated rings from human saphenous vein and human internal mammary artery, contractile responses to noradrenaline (10(-8)-10(-4) M) in the absence and presence of the alpha-adrenoceptor antagonists yohimbine (alpha(2)-adrenoceptor antagonist, 10(-8)-10(-6) M), prazosin (alpha(1)-adrenoceptor antagonist, 10(-9)-10(-7) M), 5-methyl-urapidil (5-MU, alpha(1A)-adrenoceptor antagonist, 10(-8)-10(-6) M), BMY 7378 (alpha(1D)-adrenoceptor antagonist, 10(-7)-10(-6) M), and chloroethylclonidine (CEC, irreversible alpha(1B)-adrenoceptor antagonist, 3x10(-5) M for 30 min). All experiments were carried out in the presence of 10(-7) M propranolol and 10(-5) M cocaine. In both vessel types noradrenaline evoked concentration-dependent contractions. In saphenous veins yohimbine was a potent antagonist (pA(2)-value 8.32) while prazosin, 5-MU and BMY exhibited only marginal antagonistic effects. CEC, however, significantly decreased noradrenaline-induced contractions. In contrast, in internal mammary arteries prazosin (pA(2)-value 9.65) and 5-MU (pK(B)-values 7.2-7.5) were potent antagonists, while yohimbine and BMY exhibited only weak antagonistic effects. CEC, however, significantly decreased noradrenaline-induced contractions. We conclude that in saphenous vein the contractile response to noradrenaline is mediated predominantly by alpha(2)-adrenoceptors, while in internal mammary artery it is mediated (to a major part) by alpha(1B)- and (to a minor part) by alpha(1A)-adrenoceptors.     

Discriminative stimulus effects of the α2-adrenoceptor antagonist idazoxan

Rats were trained to discriminate a dose of the ₂-adrenoceptor antagonist idazoxan (10 mg/kg IP) from saline. The discriminative stimulus produced by idazoxan was dose related and generalised to yohimbine. However, generalisation did not occur with a variety of compounds from other pharmacological categories including the ₁-adrenoceptor agonist cirazoline, the ₂-adrenoceptor antagonist prazosin, and the ₂-adrenoceptor agonist clonidine. The idazoxan stimulus was not antagonised by either prazosin or clonidine, although it was clear that idazoxan antagonised the reductions in response rate produced by clonidine. Dose-related responding on the idazoxan-associated lever was produced by the anxiolytics buspirone and ipsapirone and by their metabolite MJ 13653 (1-PP), which has previously been shown to be an ₂-adrenoceptor antagonist. In general, however, high levels of generalisation occurred with these three compounds only at doses which substantially reduced response rates. These results demonstrate that idazoxan can give rise to a discriminative stimulus which is probably mediated through antagonism at ₂-adrenoceptors although the failure of clonidine to block the idazoxan stimulus is difficult to explain.     

Characterization of α2-adrenoceptors mediating contraction of dog saphenous vein: identity with the human α2A subtype

1. In the dog saphenous vein α₁- and α₂-adrenoceptors mediate noradrenaline-induced contractions in vitro. In order to study the α₂-adrenoceptor in isolation, α₁-adrenoceptors were inactivated by treatment of tissues with the alkylating agent phenoxybenzamine (3.0 μM for 30 min) in the presence of rauwolscine (1 μM) to protect α₂-adrenoceptors.
2. Noradrenaline-induced contractions of tissues treated with phenoxybenzamine were antagonized competitively by the selective α₂-adrenoceptor antagonist rauwolscine, pK_B=8.63±0.07 (means±s.e.mean; n=3), consistent with an interaction at α₂-adrenoceptors.
3. Noradrenaline was a full agonist at α₂-adrenoceptors in dog saphenous vein. By use of the method of partial receptor alkylation and analysis of concentration-effect curve data by direct, operational model fitting methods, the affinity (pK_A) and efficacy (τ) were 5.74±0.07 and 7.50±1.05, respectively (n=6). Nine other agonists which were examined each had affinities higher than noradrenaline, but with the exception of the imidazoline, A-54741 (5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl-imidazoline) had relatively lower efficacies.
4. To compare the α₂-adrenoceptor in dog saphenous vein to the human recombinant subtypes, the affinities of twenty-one compounds were estimated in functional studies in the dog saphenous vein and in radioligand binding studies for the human α_2A, α_2B and α_2C receptor subtypes expressed in Chinese hamster lung (CHL) cells.
5. Of twenty-one compounds examined in ligand binding studies, only nine had greater than ten fold selectivity for one human receptor subtype over either of the other two. These compounds were A-54741, oxymetazoline, guanfacine, guanabenz, prazosin, spiroxatrine, tolazoline, WB 4101 and idazoxan. In dog saphenous vein, their affinities (pK_A and pK_B for agonists and antagonists respectively) were: A-54741 (pK_A=8.03±0.05), oxymetazoline (pK_A=7.67±0.09), guanfacine (pK_A=6.79±0.03); guanabenz (pK_A=7.02±0.13); prazosin (pK_B=5.19±0.08), spiroxatrine (pK_B=6.59±0.04), tolazoline (pK_B=6.21±0.07), WB 4101 (pK_B=7.42±0.09) and idazoxan (pK_B=7.11±0.08).
6. Comparisons of affinity estimates for these nine compounds at the receptor in dog saphenous vein and at the human recombinant subtypes suggest that the vascular receptor is most similar to the h α_2A subtype; correlation coefficients (r) were 0.82 (h α_2A), 0.24 (h α_2B) and 0.04 (h α_2C).

     

The effects of the α2-adrenoceptor antagonist idazoxan on sleep in normal volunteers

The effects of idazoxan, a novel antidepressant that is a potent and selective α(2)-adrenoceptor antagonist, were studied on sleep. Twelve normal male volunteers had sleep recordings made using the Oxford ambulatory system (Medilog 9000) with subsequent analysis by automatic sleep staging and visual inspection. Idazoxan was given in a dose of 40 mg three times a day for 21 days. Sleep recording on day 3 demonstrated markedly reduced indices of rapid eye movement (REM) sleep, although other sleep parameters were only minimally affected. The effect on REM persisted unchanged at day 18, however on the second day after withdrawal a rebound in REM measures was observed. These data show that idazoxan has an effect on sleep which is very similar to that of other antidepressants, and emphasize a role for noradrenaline in the regulation of REM sleep.     

Influence of MK-467, a peripherally acting α2-adrenoceptor antagonist on the disposition of intravenous dexmedetomidine in dogs

Growing evidence supports the use of (2R-trans)-N-(2-(1,3,4,7,12b-hexahydro-2'-oxo-spiro(2H-benzofuro(2,3-a)quinolizine-2,4'-imidazolidin)-3'-yl)ethyl) methanesulfonamide (MK-467), a peripherally acting α(2)-adrenoceptor antagonist, in conjunction with the sedative-anesthetic agent dexmedetomidine in animals to avoid hemodynamic compromise. We evaluated the possible effects of different doses of MK-467 on the plasma concentrations of dexmedetomidine in eight beagle dogs. Both drugs were administered intravenously. Each dog received five treatments: dexmedetomidine alone (10 μg/kg), MK-467 alone (250 μg/kg), and dexmedetomidine (10 μg/kg) combined with different doses of MK-467 (250, 500, and 750 μg/kg) in a randomized, crossover fashion. Selected pharmacokinetic parameters were calculated. The area under the time-concentration curve of dexmedetomidine was significantly greater after dexmedetomidine alone (by 101 ± 20%, mean ± 95% confidence interval) compared with that after dexmedetomidine and 250 μg/kg MK-467. Increasing the dose of the antagonist had no further effect on the exposure to dexmedetomidine. The apparent volume of distribution of dexmedetomidine was significantly smaller after dexmedetomidine alone compared with that after all treatments that included MK-467. Dexmedetomidine (10 μg/kg) did not significantly influence the plasma concentrations of MK-467 (250 μg/kg). The results suggest that the peripherally acting α(2)-adrenoceptor antagonist MK-467 markedly influenced the early disposition of dexmedetomidine without obvious effects on the later plasma concentrations of the drug.     

Pharmacological profile of a new potent and specific α2-adrenoceptor antagonist,L-657,743

Summary L-657,743, (2S,12bS)1,3-dimethylspiro (1, 3,4,5, 6,6, 7,12 b-octahydro-2-H-benzo[b]furo[2,3-a]quinolizine)-2, 4- pyrimidin-2-one, was tested in several in vitro and in vivo models for ₂-adrenoceptor antagonism. L-657,743 exhibited a high affinity ( 1 nM) for ₂-adrenoceptors labelled by [³H] rauwolscine or [3H]clonidine with a 240-fold selectivity versus ₁-adrenoceptors labelled by [³H]prazosin. L-657,743 was a potent, selective, and competitive ₂-adrenoceptor antagonist in the rat isolated vas deferens (pA₂ = 9.3 vs clonidine; pA₂ = 7.1 vs methoxamine). In vivo, L-657,743 potently blocked clonidine-induced mydriasis in the rat and stimulated cerebrocortical norepinephrine synthesis, two indices of central ₂-adrenoceptor antagonism. L-657,743 exhibited a comparatively low affinity for several monoamine receptor subtypes (D₁, D₂, 5-HT₁, 5-HT₂) in radioligand binding assays in vitro and a comparatively low potency to alter the synthesis of brain DA and 5-HT in vivo indicating a marked ₂-specificity versus other monoamine receptor mechanisms. Compared to yohimbine, L-657,743 had considerably higher ₂-antagonist potency and ₂/₁ selectivity and was significantly more ₂-specific (i.e., vs. DA, 5-HT receptors). Send of fprint requests to : D. J. Pettibone at the above address     

The effects of some α-adrenoceptor antagonists on the responses of the canine saphenous vein to B-HT 933, UK-14304 and methoxamine

Summary The benzoquinolizines Wy 25309, Wy 26703 and Wy 27127, previously reported as potent antagonists at presynaptic ₂-adrenoceptors were also potent antagonists of B-HT 933 in isolated saphenous veins of the dog confirming their activity at post synaptic ₂-adrenoceptors. Yohimbine was a more potent antagonist of B-HT 933 in isolated saphenous vein than were the Wy compounds or idazoxan contrasting with the reported potencies of these compounds at presynaptic sites in rat vas deferens and raising the possibility of differences between pre- and postsynaptic ₂adrenoceptors. Contractions of the saphenous vein were observed with high concentrations of idazoxan. Send offprint requests to K. F. Rhodes at the above address     

SAR150640, a selective β3-adrenoceptor agonist,prevents human myometrial remodelling and activation of matrix metalloproteinase in an in vitro model of chorioamnionitis

Background and purpose:

The uterine pathophysiology underlying inflammatory conditions such as chorioamnionitis remains largely unclear. As we have shown that β₃-adrenoceptors act as regulators of myometrial inflammation, we wanted to investigate the potential role of β₃-adrenoceptors in preventing uterine remodelling induced by inflammation.

Experimental approach:

The consequences of human chorioamnionitis on myometrial remodelling were characterized by Sirius Red staining and metalloproteinase (MMP) expression, and compared with the effects of incubating human myometrial samples with Escherichia coli lipopolysaccharide (LPS) in vitro. We also assessed the effect of SAR150640, a selective β₃-adrenoceptor agonist, on the production and activity of MMPs.

Key results:

Chorioamnionitis was associated with a 46% decrease in total collagen, as well as over-expression of MMP2 (+61%) and MMP9 (+84%); both effects were reproduced by incubation with LPS (10 µg·mL⁻¹, 48 h). LPS-induced over-expression of MMP2 and MMP9 in normal human myometrium was paralleled by an overactivity of the proteins. Both over-expression and overactivity were prevented by the β₃-adrenoceptor agonist SAR150640 in a concentration-dependent manner. SAR150640, by itself, did not exhibit any effect on MMP production in control tissues.

Conclusions and implications:

This study shows that inflammation was associated with an intense remodelling of human myometrium, a process likely to be explained by MMP activation. Our study emphasizes the potential therapeutic relevance of β₃-adrenoceptor agonists to the treatment of preterm labour and other uterine inflammatory conditions.     

The effects of ethanol in combination with the α2-adrenoceptor agonist dexmedetomidine and the α2-adrenoceptor antagonist atipamezole on brain monoamine metabolites and motor performance of mice

The time course of the effects of ethanol alone and in combination with the selective α₂-adrenoceptor agonist dexmedetomidine and the α-adrenoceptor antagonist atipamezole was studied in NIH-Swiss mice. Core body temperature, rotarod performance, motility and changes in the noradrenaline, dopamine, and 5-hydroxytryptamine (5-HT) metabolite contents of different brain parts (limbic forebrain, striatum, lower brainstem, the rest of the forebrain + midbrain and hypothalamus) were measured. Atipamezole (3 mg/kg) attenuated the hypothermia induced by either ethanol (3 g/kg) alone or ethanol in combination with dexmedetomidine (0.3 mg/kg). Atipamezole shortened the duration of the ethanol-impaired and ethanol + dexmedetomidine-impaired rotarod performance. Further, atipamezole prevented the decreased motility due to the combined treatment with ethanol and dexmedetomidine. Ethanol increased 3-methoxy-4-hydroxyphenylethylene glycol (MHPG), homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) values. Dexmedetomidine alone decreased MHPG and 5-hydroxyindoleacetic acid (5-HIAA) concentrations and increased DOPAC and HVA values. Dexmedetomidine combined with ethanol resulted in a further increase in DOPAC and HVA values. Pharmacokinetic parameters did not contribute to this antagonism of ethanol's effects by atipamezole, nor did the antagonism observed in rotarod performance or hypothermia seem to correlate with the changes seen in the brain noradrenaline and dopamine or 5-HT metabolism. In conclusion, these findings suggest that several ethanol effects are not mediated via direct activation of α₂-adrenoceptors, even though some of ethanol's behavioral and physiological effects may be antagonized by coadministration of α₂-adrenoceptor antagonists.     

The effect of selective α1- and α2-adrenoceptor stimulation on intraocular pressure in the conscious rabbit

Summary The influence of topically applied selective ₁- and ₂-adrenoceptor agonists on intraocular pressure and the diameter of the pupil was investigated in conscious rabbits. Selective stimulation of the ₁-subtype of receptors induced an elevation in intraocular pressure, accompanied by mydriasis, whereas stimulation of the ₂-subtype caused a marked and dose-dependent ocular hypotensive response, which was blocked by the selective ₂-adrenoceptor antagonist yohimbine. ₂-Agonists induced neither macroscopic ocular side effects, nor an effect on the pupil size. Possibly, the subclass of ₂-adrenoceptor stimulating drugs represent a group of new antiglaucomatous agents.     

Effects ofβ-adrenoceptor antagonist administration on β2-adrenoceptors density in human lymphocytes

Abrupt withdrawal of beta-adrenoceptor antagonists may lead to "rebound-effects". To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years. Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; concomitantly PRA and heart rate were reduced. During treatment beta 2-adrenoceptor density remained elevated. After withdrawal of propranolol PRA reached pre-drug levels rapidly, while heart rate was significantly enhanced. Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of ICYP to beta 2-adrenoceptors was not changed during or after treatment. Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment. After withdrawal, PRA reached rapidly pre-drug levels, whereas beta 2-adrenoceptor density was still after 4 days significantly diminished. The KD-values for ICYP, however, were not changed. During and after treatment heart rate was not affected. Alprenolol treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect beta 2-adrenoceptor density. It is concluded, that the ISA may play an important role in modulating beta 2-adrenoceptor density and hence tissue responsiveness to beta-adrenoceptor stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)     

Evidence in favour of a selective α1-adrenoceptor blocking action of WB 4101 in vivo

Summary The -adrenoceptor blocking potency of WB 4101 at ₁- and ₂-adrenoceptors has been investigated in pithed rats.WB 4101 was approximately 97 times more potent at antagonizing the vasopressor responses produced by the selective ₁-adrenoceptor agonist phenylephrine, than those produced by the selective ₂-adrenoceptor agonist M-7.A dose of WB 4101 (3 mg/kg) that caused extensive blockade of vascular ₁-adrenoceptors, but little or no blockade of vascular ₂-adrenoceptors, exerted no significant blockade of the presynaptic ₂-adrenoceptors in the rat heart.The results support the view that WB 4101 is a highly selective antagonist at ₁-adrenoceptors in vivo.     

Further studies on (±)-YM-12617, a potent and selective α1-adrenoceptor antagonist and its individual optical enantiomers

Summary YM-12617, 5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide HCl is structurally novel, an extremely potent and highly selective ₁-adrenoceptor antagonist. An asymmetric center exists at the -carbon atom in the phenethylamine portion of YM-12617, therefore two optical enantiomers exist. -Adrenoceptor blocking properties and hypotensive activities of YM-12617 and its enantiomers have been compared in vitro and in vivo. 1. In the isolated rabbit aorta, R(–)- and S(+)-YM-12617 competitively antagonized phenylephrine-induced contraction with pA₂ values of 9.95 and 7.69, respectively. Although R(–)- and S(+)-YM-12617 were also competitive antagonists toward UK-14,304 at prejunctional ₂-adrenoceptors in the isolated guinea-pig ileum, the affinities of R(–)-YM-12617 (pA₂ = 6.18) and S(+)-YM-12617 (pA₂ = 5.64) for these receptors were 5,900 and 110 times lower than those displayed for postjunctional ₁-adrenoceptors in the isolated rabbit aorta. 2. R(–)- and S(+)-YM-12617 displaced both ³H-prazosin and ³H-idazoxan binding to rat brain membranes; however, the affinities of the R(–)- and S(+)-enantiomers for ₁-adrenoceptors (pK_i = 9.95 and 7.83, respectively) were 21,000 and 72 times higher than those for ₂-adrenoceptors (pK _i = 5.62 and 5.97), respectively. 3. Based on pA₂ values obtained in the isolated tissues and pK _i values in the binding assays, R(–)-YM-12617 was 132–182 times more potent than S(+)-YM-12617 as an antagonist at ₁-adrenoceptors. In contrast, the R(–)- and S(+)-enantiomers were similar in potency at blocking ₂-adrenoceptors. 4. In normotensive pithed rats, R(–)- and S(+)-YM-12617 preferentially antagonized the ₁-adrenoceptor mediated pressor effect of phenylephrine with DR₁₀ values of 1.38 and 705 g/kg i. v., respectively, although a high dose (3,000 g/kg i.v.) also inhibited the effect of UK-14,304 at postjunctional ₂-adrenoceptors. R(–)-YM-12617 exhibited an over 2,000-fold selectivity for postjunctional ₁-adrenoceptors, and R(–)-YM-12617 was over 500 times more potent than S(+)-YM-12617 in antagonizing postjunctional ₁-adrenoceptors based on DR₁₀ values. 5. In anesthetized rats, R(–)- and S(+)-YM-12617 dose-dependently produced hypotension with ED₂₀ values, doses required decreased mean blood pressure by 20%, of 0.64 and 61 g/kg i. v., respectively. R(–)-YM-12617 exerted a 95 times more potent hypotensive activity than S(+)-YM-12617, and its isomeric activity ratio was consistent with that for ₁-adrenoceptors but not ₂-adrenoceptors. 6. The present results suggest that the high stereoselectivity of the optical enantiomers of YM-12617 is in the ₁-adrenoceptor, but not in the ₂-adrenoceptor, and their antagonist potency for ₁-adrenoceptors is likely to contribute to the hypotensive effect. Send offprint requests to K. Honda     

In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats

To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat β-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC₅₀ value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat β₃-adrenoceptors. The EC₅₀ values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat β₁-adrenoceptors and were sumless and 0.1 for β₂-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC₅₀ value of 290 nmol/L. The concentration–response curve of mirabegron was affected neither by the β₁-adrenoceptor selective antagonist CGP-20712A nor by the β₂-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of β₃-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.     

The effects and after effects of the α2-adrenoceptor antagonist idazoxan on mood, memory and attention in normal volunteers

Idazoxan, an α( 2)-adrenoceptor antagonist, is an effective antidepressant with a mode of action different from that of conventional antidepressants. As it is used as an antidepressant it is important to know whether there are any unwanted CNS side effects. Study of its effects will also provide information on the relationship between noradrenergic function and mood and performance. Twelve normal male volunteers who were given the drug (40 mg orally three times daily for 21 days) were compared with 12 matched controls. A computerized test battery was used to assess mood and various aspects of memory and attention. Many of the tests of memory and attention in the battery have been widely used over the last 20 years, and in addition two new selective attention tasks were included. The subjects were tested 3 days before starting the drug, on days 3 and 17 while on the drug, and after they had stopped taking the drug (4 days after and 24 days after). Control subjects followed a similar testing schedule. The results showed that the drug had no effect on mood, logical reasoning, retrieval from semantic memory or sustained attention. However, the drug did improve one aspect of selective attention (the place repetition effect), although this effect was only observed on the third day on the drug. Overall, the results suggest that idazoxan produces selective performance improvements, and that the measures of selective attention used here may be more sensitive indicators of drug effects than some of the traditional tasks currently in use.     

In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist

BACKGROUND AND PURPOSE

Studies of the role of the prostaglandin EP₂ receptor) have been limited by the availability of potent and selective antagonist tools. Here we describe the in vitro/in vivo pharmacological characterization of a novel EP₂ receptor antagonist, PF-04418948 (1-(4-fluorobenzoyl)-3-{[(6-methoxy-2-naphthyl)oxy]methyl} azetidine-3-carboxylic acid).

EXPERIMENTAL APPROACH

Functional antagonist potency was assessed in cell-based systems expressing human EP₂ receptors and native tissue preparations from human, dog and mouse. The selectivity of PF-04418948 was assessed against related receptors and a panel of GPCRs, ion channels and enzymes. The ability of PF-04418948 to pharmacologically block EP₂ receptor function in vivo was tested in rats.

KEY RESULTS

PF-04418948 inhibited prostaglandin E₂ (PGE₂)-induced increase in cAMP in cells expressing EP₂ receptors with a functional K_B value of 1.8 nM. In human myometrium, PF-04418948 produced a parallel, rightward shift of the butaprost-induced inhibition of the contractions induced by electrical field stimulation with an apparent K_B of 5.4 nM. In dog bronchiole and mouse trachea, PF-04418948 produced parallel rightward shifts of the PGE₂-induced relaxation curve with a K_B of 2.5 nM and an apparent K_B of 1.3 nM respectively. Reversal of the PGE₂-induced relaxation in the mouse trachea by PF-04418948 produced an IC₅₀ value of 2.7 nM. Given orally, PF-04418948 attenuated the butaprost-induced cutaneous blood flow response in rats. PF-04418948 was selective for EP₂ receptors over homologous and unrelated receptors, enzymes and channels.

CONCLUSIONS AND IMPLICATIONS

PF-04418948 is an orally active, potent and selective surmountable EP₂ receptor antagonist that should aid further elaboration of EP₂ receptor function.

LINKED ARTICLE

This article is commented on by Birrell and Nials, pp. 1845–1846 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2011.01494.x